ABSTRACT
INTRODUCTION
A NY INTRAOCULAR INTERVENTION is associated with the risk of an infectious endophthalmitis. Intravitreal injections of drugs exhibit the additional risk of a toxic reaction to the injected substance. Because of a current change in paradigm to consider the vitreous cavity as a drug reservoir for the medical treatment of macular diseases, intravitreal injections of drugs, particularly of bevacizumab and ranibizumab, have exponentially increased in frequency within the last year for the therapy of exudative age-related macular degeneration (AMD) and macular edema of various etiologies. [1] [2] [3] [4] [5] Whereas reports have been accumulating about the risk of a postinjection of endophthalmitis after the intravitreal application of triamcinolone acetonide (TA), 6, 7 information about the same risk after an intravitreal injection of bevacizumab have been scarce to date. It was, therefore, the aim of this study to evaluate the rate of postinjection infections and toxic inflammations after an intravitreal injection of bevacizumab.
to 684 eyes of 625 patients. This study was a retrospective analysis of patients who received a standard treatment. The patients were fully informed about the experimental character of the treatment and signed an informed consent. A votum of an ethics committee was not obtained.
The first injections were performed in October 2005, and the last injection was carried out 4 weeks before statistical analysis. There were 684 (56.2%) primary injections, 313 (25.7%) second injections, 193 (15.8%) third injections, 23 (1.9%) fourth injections, and 5 (0.4%) fifth injections. The injections were carried out for the treatment of exudative AMD.
The drug was prepared by the pharmacy under sterile conditions. The injections were performed under sterile conditions in the operation theater as any other intravitreal surgical procedure. Prior to the intravitreal injection, topical Betadine (povidone-iodine) 5% (Alcon, Ft Worth, TX) was applied, and following this, the patient was completely draped. A lid speculum was inserted, a paracentesis carried out to decrease the volume of the eye, and the injection was performed through a sharp 27-gauge needle through the inferior pars plana, at 3-3.5 mm from the limbus.
All patients received a topical antibiotic treatment with neomycin and polymyxin and were examined within 1 week after the injections in the hospital or by the referring ophthalmologist in a vicinity of usually less than 30 km. The reinjections were performed usually in an interval of 5 weeks. Follow-up after each injection was at least 4 weeks.
RESULTS
A 55-year-old female patient developed an infectious endophthalmitis 3 days after her second intravitreal injection as the treatment of a detachment of the retinal pigment epithelium. After the first injection, visual acuity had increased from 0.6 to 0.8 before she received the second treatment. When the patient presented with endophthalmitis, visual acuity was light perception, and the vitreous was densely infiltrated. A pars plana vitrectomy was performed with silicone oil endotamponade. Silicone oil for endotamponade was taken owing to its indirect antiphlogistic effect.
Two (2) weeks after silicone oil removal, the patient's visual acuity improved to 0.2, with the retinal pigment epithelium attached and no longer showing signs of an exudative maculopathy. A microbiological culture taken during vitrectomy did not reveal a causative organism.
In none of the other eyes were signs of an infectious or noninfectious endophthalmitis observed, such as the marked Tyndall phenomenon in the anterior chamber(Ͼ ϩϩ), inflammatory cells in the anterior chamber of the vitreous cavity, or a marked amorphous opacification of the vitreous as a sign of a toxic reaction.
CONCLUSIONS
In conclusion, the rate of infectious endophthalmitis after an intravitreal injection of bevacizumab (1.5 mg) was approximately 1 per 1000 injections. This number is similar to intravitreal injections of other drugs, such as triamcinolone and ranibizumab. [5] [6] [7] Compared with other drugs applied intravitreally, intravitreal bevacizumab may not be associated with a higher rate of intraocular noninfectious inflammation.
